Akari Therapeutics Plc ADR

Akari Therapeutics Plc ADR is an American Depositary Receipt representing shares of Akari Therapeutics PLC, a clinical-stage biopharmaceutical company focused on oncology. The company develops next-generation antibody-drug conjugates (ADCs) featuring novel, proprietary payloads that harness powerful biology to target cancer cells precisely. Its lead payload, PH1, disrupts RNA splicing by modulating the spliceosome, a critical cellular mechanism for protein production essential to tumor survival and proliferation. Key pipeline candidates include AKTX-101, which targets the Trop2 receptor prevalent on various cancer cells and uses a proprietary linker for direct delivery of PH1 into tumors, minimizing off-target effects, and AKTX-102, directed at CEACAM5, a validated antigen in multiple solid tumors. Akari Therapeutics PLC operates within the healthcare sector, advancing precision therapies to address unmet needs in cancer treatment. Headquartered in Boston, Massachusetts, it emphasizes bifunctional ADCs designed for enhanced efficacy and safety profiles in solid tumor indications.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Abizer Gaslightwala

Employees

5

Headquarters

Tampa, FL, United States

Website

www.akaritx.com